June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
In-Office Vitreous Sampling shows that Levels of MMP-9 Correlate with the Severity of Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Ann Igbre
    National Retina Institute, Towson, MD
  • Stephanie Ecker
    National Retina Institute, Towson, MD
  • Joshua Hines
    National Retina Institute, Towson, MD
  • Bert Glaser
    National Retina Institute, Towson, MD
  • Footnotes
    Commercial Relationships Ann Igbre, None; Stephanie Ecker, Ocular Proteomics LLC (E); Joshua Hines, Ocular Proteomics (E); Bert Glaser, Ocular Proteomics, LLC (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 276. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ann Igbre, Stephanie Ecker, Joshua Hines, Bert Glaser; In-Office Vitreous Sampling shows that Levels of MMP-9 Correlate with the Severity of Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):276. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The purpose of this study is to explore potential proteomic biomarkers in vitreous samples of patients with different severities of proliferative diabetic retinopathy (PDR).

Methods: Ninety six (96) in-office vitreous aspirates were obtained from 42 patients with PDR and 24 age matched non-diabetic controls. All 96 samples were probed against 44 pathway proteins using reverse phase protein microarray (RPPM) technology.

Results: When comparing PDR patients who had visual acuity (VA) better than 20/ 200 vs. patients with VA worse than 20/200 there were 20 proteins that had significantly different levels between the 2 groups. Among these proteins, MMP-9 had significantly higher vitreous levels in patients with better VA (<20/200) vs. patients with worse VA (>20/200). Between the two groups, the statistical significance is highest for MMP-9 among the 20 proteins (P=0.006, ROC: AUC= 0.7837, P= 0.006). Those eyes with better VA demonstrated significant correlation of MMP-9 with pro-inflammatory cytokines, while in those with worse VA MMP-9 correlates with pro-angiogenic cytokines. Additionally, MMP- 9 levels are higher in the vitreous of non-diabetic controls than in the vitreous from PDR patients (P<0.0001, ROC: AUC= 0.7979 P<0.0001), regardless of VA.

Conclusions: In-office vitreous sampling reveals MMP-9 levels in eyes with PDR to be higher in eyes with better VA. Vitreous levels of MMP-9 were highest in eyes of non-diabetic controls. In addition, evidence was found for activities of both pro-inflammatory and pro-angiogenic pathways in a manner that indicattes different roles for these important pathways in disease outcomes. This suggests a possible role for MMP-9 as a predictive biomarker of disease progression and severity as well as providing an enhanced understanding of the biochemical pathways involved in disease progression to provide the basis for improved disease management.

Keywords: 663 proteomics • 499 diabetic retinopathy • 490 cytokines/chemokines  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.